IGM Ebitda from 2010 to 2024

IGMS Stock  USD 7.15  1.07  13.02%   
IGM Biosciences EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA is likely to outpace its year average in 2024. From the period from 2010 to 2024, IGM Biosciences EBITDA quarterly data regression had mean square error of 2708.6 T and mean deviation of  78,388,631. View All Fundamentals
 
EBITDA  
First Reported
2018-09-30
Previous Quarter
-49.1 M
Current Value
-62.1 M
Quarterly Volatility
21.8 M
 
Covid
Check IGM Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IGM Biosciences' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 8.7 M or Interest Expense of 8.3 M, as well as many indicators such as Price To Sales Ratio of 194, Dividend Yield of 0.0 or PTB Ratio of 2.25. IGM financial statements analysis is a perfect complement when working with IGM Biosciences Valuation or Volatility modules.
  
Check out the analysis of IGM Biosciences Correlation against competitors.
For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.

Latest IGM Biosciences' Ebitda Growth Pattern

Below is the plot of the Ebitda of IGM Biosciences over the last few years. It is IGM Biosciences' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in IGM Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

IGM Ebitda Regression Statistics

Arithmetic Mean(74,221,673)
Coefficient Of Variation(127.18)
Mean Deviation78,388,631
Median(10,986,000)
Standard Deviation94,398,497
Sample Variance8911.1T
Range242.4M
R-Value(0.85)
Mean Square Error2708.6T
R-Squared0.72
Significance0.000067
Slope(17,882,899)
Total Sum of Squares124755.1T

IGM Ebitda History

2024-240.7 M
2023-253.4 M
2022-221.9 M
2021-160.8 M
2020-82.3 M
2019-43.9 M
2018-22.5 M

About IGM Biosciences Financial Statements

IGM Biosciences shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although IGM Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in IGM Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on IGM Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-253.4 M-240.7 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.